ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
Ram Ratna Wires Limited received a GST show-cause-cum-demand notice for INR 29.23 Crores regarding financial years 2020-21 to 2023-24.
Ram Ratna Wires Limited held its 34th Annual General Meeting on August 04, 2026. All proposed resolutions were passed by the members with the requisite majority.
Ram Ratna Wires (RRWL) reported robust Q1 FY27 growth, with Revenue up 88.6% and PAT up 120.8% YoY. Strategy focuses on diversification into copper tubes and renewable energy segments.
Ram Ratna Wires reported Q1 FY27 revenue of ₹1,853.3 Crore and PAT of ₹35.2 Crore, reflecting strong year-over-year growth in its manufacturing operations.
Ram Ratna Wires Ltd reported revenue from operations of ₹1,853 Cr (+88.6% YoY) and net profit of ₹35.2 Cr (+121.4% YoY) for Q1 FY27.
Ram Ratna Wires Limited has scheduled a board meeting for July 31, 2026. The meeting will consider unaudited financial results for the quarter ended June 2026.
Ram Ratna Wires Limited filed its quarterly shareholding pattern for the period ended June 30, 2026, in accordance with SEBI regulatory requirements.
Ram Ratna Wires convened its 34th AGM for August 4, 2026. Key resolutions include a ₹2.50 per share dividend and enhancement of borrowing limits.
Ram Ratna Wires Limited submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details the company's ESG performance and statutory compliance.
Ram Ratna Wires Limited submitted its 34th Annual Report for FY 2025-26. The company's Annual General Meeting is scheduled for August 04, 2026.
Ram Ratna Wires Ltd announced a final dividend of Rs.2.50 per share for FY 2025-26. Record date is set for 22 July 2026.
Ram Ratna Wires reported strong FY26 performance with consolidated revenue reaching ₹5,176.6 Cr. Strategy focuses on diversifying into high-margin copper tubes and pipes at the Bhiwadi facility.
Ram Ratna Wires recommended a final dividend of ₹0.50 per equity share for FY 2025-26. Payment is scheduled for completion by September 02, 2026.
Ram Ratna Wires re-appointed Payal Agarwal as Independent Director for a five-year term. The Board also re-appointed Tax, Cost, and Internal Auditors for FY 2026-27.
Ram Ratna Wires reported ₹5,176.6 Crore revenue for FY26, driven by strong Q4 momentum. Net profit surged 110% YoY, reflecting improved product mix and demand.
Ram Ratna Wires Ltd reported revenue from operations of ₹1,753 Cr (+83.2% YoY) and net profit of ₹39.2 Cr (+109.6% YoY) for Q4 FY26.
Ram Ratna Wires reported FY26 audited results and recommended a Rs. 2.50 dividend. The board also scheduled the 34th AGM for August 04, 2026.
Ram Ratna Wires Limited scheduled a board meeting for May 26, 2026. Directors will consider audited annual financial results and a final dividend declaration.
Ram Ratna Wires Limited submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The auditor confirmed total regulatory compliance across all SEBI listing norms.
Ram Ratna Wires Limited clarified to BSE that the recent increase in security trading volume is purely market-driven. The company confirmed it has disclosed all material events under SEBI LODR Regulations and has no pending information that could affect price or volume.
Ram Ratna Wires Limited clarified to NSE that the recent increase in trading volume is purely market-driven. The company confirmed there is no pending material information or announcement that could affect its stock price or volume. It remains committed to all regulatory disclosure requirements under SEBI LODR Regulations.
Ram Ratna Wires Ltd submitted its quarterly certificate under Regulation 74(5) of SEBI (DP) Regulations for the period ended March 31, 2026. The certificate, issued by Datamatics Business Solutions Limited, confirms that share certificates received for dematerialization were processed, mutilated, and cancelled within the prescribed 15-day timeline.